Last Price
126.13
Today's Change
-0.71 (0.55%)
Day's Change
121.56 - 128.039
Trading Volume
1,169,757
Market Cap
15 Billion
Shares Outstanding
121 Million
Avg Volume
930,633
Avg Price (50 Days)
116.47
Avg Price (200 Days)
114.96
PE Ratio
54.84
EPS
2.30
Earnings Announcement
28-Apr-2025
Previous Close
126.84
Open
125.47
Day's Range
121.56 - 128.04
Year Range
97.32 - 129.5
Trading Volume
1,210,150
1 Day Change
-0.56%
5 Day Change
1.92%
1 Month Change
12.62%
3 Month Change
4.21%
6 Month Change
0.88%
Ytd Change
12.62%
1 Year Change
15.44%
3 Year Change
-27.63%
5 Year Change
35.81%
10 Year Change
176.66%
Max Change
3710.57%
No result.
Sector: Healthcare - Healthcare
Industry: Diagnostics & Research
Description:
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.